COMMUNIQUÉS West-GlobeNewswire

Quipt Home Medical Corp. Announces Filing and Mailing of Proxy Statement and Information Circular and Receipt of Interim Order in Connection With Plan of Arrangement
04/02/2026
CINCINNATI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ Company ”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is [...]
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
04/02/2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
04/02/2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026 [...]
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Max Force Power Male Enhancement Gummies Product Information Updated as Consumer Interest in Male Vitality Supplement Options Grows in 2026
05/02/2026
An informational overview examining male enhancement supplement category trends, publicly available ingredient disclosures, consumer evaluation criteria, and what adults researching male vitality supplement options [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/02/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Olema Oncology to Participate in Upcoming Investor Conferences
04/02/2026
SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Monthly information on share capital and company voting rights
04/02/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
05/02/2026
CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
STERIS Announces Financial Results for Fiscal 2026 Third Quarter
04/02/2026
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook [...]
CC Pharma, filiale de Tilray, figure parmi le classement TOP 100 Innovator en Allemagne
04/02/2026
Cette distinction récompense CC Pharma dans son rôle de leader de l’innovation et de partenaire de référence du marché pharmaceutique européen DENSBORN, Allemagne, 04 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la [...]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/02/2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the [...]
Invisalign Invites Los Angeles Orthodontist to Keynote on Clear Aligners
04/02/2026
Board-certified orthodontist with over 5,000 Invisalign cases reveals treatment timelines, costs, and patient care standards LOS ANGELES, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Align Technology, the company that manufactures [...]
His Choice Health Launches Unified Men’s Health Brand After 10,000+ Vasectomy Procedures
04/02/2026
Physician-Led, Cash-Pay Platform Combines Two High-Volume Practices to Expand Access to Evidence-Based Men’s Health Care Raleigh, NC, Feb. 04, 2026 (GLOBE NEWSWIRE) -- His Choice Raleigh and His Choice Durham today [...]
Interim report 2025/26 - Organic growth despite challenges in the North American market
04/02/2026
ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was [...]
New NMDP-Sponsored Trial Data Show Comparable Patient-Reported Outcomes and Survival Across Levels of Genetic Mismatch
04/02/2026
ACCESS trial results at the 2026 Tandem Meetings reinforce mismatched unrelated donors as safe, effective and well-tolerated option Practice-advancing research conducted through CIBMTR demonstrates collaborative, [...]
ChemoMetec enters Letter of Intent with Roche Diagnostics
04/02/2026
ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating [...]
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
04/02/2026
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]

Pages